دورية أكاديمية
Development of CD46 targeted alpha theranostics in prostate cancer using 134 Ce/ 225 Ac-Macropa-PEG 4 -YS5.
العنوان: | Development of CD46 targeted alpha theranostics in prostate cancer using 134 Ce/ 225 Ac-Macropa-PEG |
---|---|
المؤلفون: | Bobba KN; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States., Bidkar AP; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States., Wadhwa A; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States., Meher N; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States., Drona S; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States., Sorlin AM; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States., Bidlingmaier S; Department of Anesthesia, University of California, San Francisco, California 94110, United States., Zhang L; Department of Medicine and the Department of Epidemiology and Biostatistics, University of California, Berkeley, California, United States., Wilson DM; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States., Chan E; Department of Pathology, University of California, San Francisco, California 94110, United States., Greenland NY; Department of Pathology, University of California, San Francisco, California 94110, United States., Aggarwal R; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States.; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, United States., VanBrocklin HF; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States., He J; Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, 22908, United States., Chou J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States.; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, United States., Seo Y; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States., Liu B; Department of Anesthesia, University of California, San Francisco, California 94110, United States.; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States., Flavell RR; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States.; Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94158-2517, United States. |
المصدر: | Theranostics [Theranostics] 2024 Jan 27; Vol. 14 (4), pp. 1344-1360. Date of Electronic Publication: 2024 Jan 27 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Wyoming, N.S.W. : Ivyspring International Publisher, 2011- |
مواضيع طبية MeSH: | Precision Medicine* , Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/radiotherapy, Male ; Mice ; Animals ; Humans ; Mice, Nude ; Tissue Distribution ; Radiopharmaceuticals ; Chelating Agents ; Membrane Cofactor Protein |
مستخلص: | Rationale: 225 Ac, a long-lived α-emitter with a half-life of 9.92 days, has garnered significant attention as a therapeutic radionuclide when coupled with monoclonal antibodies and other targeting vectors. Nevertheless, its clinical utility has been hampered by potential off-target toxicity, a lack of optimized chelators for 225 Ac, and limitations in radiolabeling methods. In a prior study evaluating the effectiveness of CD46-targeted radioimmunotherapy, we found great therapeutic efficacy but also significant toxicity at higher doses. To address these challenges, we have developed a radioimmunoconjugate called 225 Ac-Macropa-PEG Competing Interests: Competing Interests: The authors have declared that no competing interest exists. (© The author(s).) |
References: | JCI Insight. 2018 Sep 6;3(17):. (PMID: 30185663) Science. 2001 Nov 16;294(5546):1537-40. (PMID: 11711678) Curr Radiopharm. 2018;11(3):200-208. (PMID: 29732998) Appl Radiat Isot. 2002 Dec;57(6):841-7. (PMID: 12406626) Prostate Cancer Prostatic Dis. 2021 Sep;24(3):880-890. (PMID: 33746213) Methods Enzymol. 2017;585:91-110. (PMID: 28109445) Mol Pharm. 2018 Apr 2;15(4):1457-1466. (PMID: 29502411) Cancer Biother Radiopharm. 2018 Oct;33(8):336-348. (PMID: 29889562) J Nucl Med. 2023 Apr;64(4):549-554. (PMID: 36396453) Clin Cancer Res. 2019 Jan 15;25(2):868-880. (PMID: 30352909) J Nucl Med. 2022 Apr;63(4):584-590. (PMID: 34385334) Bioconjug Chem. 2006 Nov-Dec;17(6):1551-60. (PMID: 17105236) J Nucl Med. 2016 Dec;57(12):1941-1944. (PMID: 27390158) Am Soc Clin Oncol Educ Book. 2014;:e126-31. (PMID: 24857092) Mol Cancer Ther. 2010 Jul;9(7):2131-41. (PMID: 20587664) Pharmacol Res. 2020 Oct;160:105070. (PMID: 32659429) Mol Cancer Ther. 2008 Mar;7(3):569-78. (PMID: 18319332) N Engl J Med. 2013 Jul 18;369(3):213-23. (PMID: 23863050) Semin Nucl Med. 2020 Mar;50(2):119-123. (PMID: 32172796) Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717. (PMID: 28963750) Clin Cancer Res. 2023 Dec 18;:. (PMID: 38109209) Bioconjug Chem. 2021 Jul 21;32(7):1263-1275. (PMID: 34056896) J Nucl Med. 2023 Jul;64(7):1076-1082. (PMID: 37201957) Phys Med Biol. 2002 Feb 21;47(4):615-29. (PMID: 11900194) Molecules. 2022 Aug 04;27(15):. (PMID: 35956909) Clin Cancer Res. 2023 May 15;29(10):1916-1928. (PMID: 36917693) J Radiol Prot. 2019 Jun;39(2):387-398. (PMID: 30716726) Molecules. 2020 Dec 22;26(1):. (PMID: 33374953) J Nucl Med. 2018 Jun;59(6):878-884. (PMID: 29545378) Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157632. (PMID: 36895851) Curr Radiopharm. 2011 Oct;4(4):306-20. (PMID: 22202153) N Engl J Med. 2021 Sep 16;385(12):1091-1103. (PMID: 34161051) J Clin Invest. 2016 Dec 1;126(12):4640-4653. (PMID: 27841764) Nucl Med Biol. 2021 Jan;92:228-240. (PMID: 33558017) J Cancer Res Clin Oncol. 2018 Sep;144(9):1685-1699. (PMID: 29959569) Theranostics. 2022 Oct 17;12(17):7203-7215. (PMID: 36438496) J Exp Clin Cancer Res. 2023 Mar 11;42(1):61. (PMID: 36906664) Clin Cancer Res. 2021 Mar 1;27(5):1305-1315. (PMID: 33293372) Lancet. 2021 Feb 27;397(10276):797-804. (PMID: 33581798) J Nucl Med. 2017 Oct;58(10):1624-1631. (PMID: 28408529) Protein Cell. 2018 Jan;9(1):33-46. (PMID: 27743348) J Nucl Med. 2021 Jul 1;62(7):1012-1015. (PMID: 33127622) J Med Chem. 2022 May 12;65(9):6419-6430. (PMID: 35442675) J Nucl Med. 2022 Jul 21;:. (PMID: 35863893) J Clin Oncol. 2023 Nov 3;:JCO2300573. (PMID: 37922438) Bioconjug Chem. 2017 Sep 20;28(9):2211-2223. (PMID: 28767228) J Mater Chem B. 2021 Apr 7;9(13):2993-2997. (PMID: 33725072) Nat Chem. 2021 Mar;13(3):284-289. (PMID: 33318671) Int J Urol. 2018 Apr;25(4):345-351. (PMID: 29396873) |
معلومات مُعتمدة: | R01 CA279203 United States CA NCI NIH HHS |
فهرسة مساهمة: | Keywords: PEG linkers; YS5 antibody; actinium-225; cerium-134; macropa; targeted alpha therapy; theranostics |
المشرفين على المادة: | 0 (Radiopharmaceuticals) 0 (Chelating Agents) 0 (CD46 protein, human) 0 (Membrane Cofactor Protein) |
تواريخ الأحداث: | Date Created: 20240223 Date Completed: 20240226 Latest Revision: 20240309 |
رمز التحديث: | 20240309 |
مُعرف محوري في PubMed: | PMC10879874 |
DOI: | 10.7150/thno.92742 |
PMID: | 38389832 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1838-7640 |
---|---|
DOI: | 10.7150/thno.92742 |